Literature DB >> 10971829

Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus.

R Paraná1, M Cruz, L Lyra, T Cruz.   

Abstract

Autoimmune thyroiditis has been frequently reported during interferon monotherapy for hepatitis C, but there are few reports concerning subacute thyroiditis. Recently, combination therapy of IFN plus ribavirin has become the preferred therapeutic schedule for chronic hepatitis C. Similarly to interferon monotherapy, there are no reports concerning subacute thyroiditis during combination therapy. We described four episodes of subacute thyroiditis occurring in three patients during antiviral combination therapy. All patients had symptoms compatible with hyperthyroidism, which could be misdiagnosed as IFN side-effects. The antiviral treatment was continued in all three patients and thyroid function increased progressively with pharmacological treatment for hyperthyroidism. We concluded that subacute thyroiditis may be a complication of combination antiviral therapy and should be investigated in patients presenting with compatible symptoms, in order to differentiate from IFN side-effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971829     DOI: 10.1046/j.1365-2893.2000.00247.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  5 in total

Review 1.  Hepatitis C and interferon induced thyroiditis.

Authors:  Yaron Tomer
Journal:  J Autoimmun       Date:  2010-05       Impact factor: 7.094

Review 2.  Interferon alpha treatment and thyroid dysfunction.

Authors:  Yaron Tomer; Jason T Blackard; Nagako Akeno
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

Review 3.  Interferon induced thyroiditis.

Authors:  Yaron Tomer; Francesca Menconi
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

4.  Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study.

Authors:  G Mazziotti; F Sorvillo; G Stornaiuolo; M Rotondi; F Morisco; M Ruberto; M Cioffi; G Amato; N Caporaso; G B Gaeta; C Carella
Journal:  J Endocrinol Invest       Date:  2002 Jul-Aug       Impact factor: 4.256

5.  A case of hyperthyroidy developing in "pegylated-interferon" therapy.

Authors:  Mehmet Aslan; Yasar Nazligul; Nurten Aksoy; Nevin Yilmaz
Journal:  Dig Dis Sci       Date:  2007-03-20       Impact factor: 3.487

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.